Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,119 shares of the biopharmaceutical company’s stock after purchasing an additional 2,643 shares during the period. Mediolanum International Funds Ltd’s holdings in Alnylam Pharmaceuticals were worth $14,262,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ALNY. First Horizon Corp grew its position in Alnylam Pharmaceuticals by 20.7% during the 4th quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 28 shares during the period. Yousif Capital Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 1.8% in the 4th quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company’s stock valued at $666,000 after buying an additional 29 shares during the period. Daiwa Securities Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after buying an additional 35 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares during the last quarter. Finally, Everpar Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 6.3% during the fourth quarter. Everpar Advisors LLC now owns 620 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 37 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Morgan Stanley boosted their price target on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the company an “equal weight” rating in a report on Friday, July 10th. Royal Bank Of Canada dropped their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a research note on Friday, May 1st. Citigroup started coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 target price for the company. Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 7th. Finally, Chardan Capital restated a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $455.31.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $267.47 on Monday. The company has a fifty day simple moving average of $294.16 and a 200-day simple moving average of $320.56. The firm has a market capitalization of $35.71 billion, a price-to-earnings ratio of 73.08 and a beta of 0.27. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 52-week low of $266.43 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company’s revenue for the quarter was up 96.4% on a year-over-year basis. During the same period last year, the firm posted ($0.44) earnings per share. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.26 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.